- Home
- GPRK vs PROK Comparison
GPRK vs PROK Comparison
Compare GPRK & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRK | PROK |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.8M | 331.2M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GPRK | PROK |
|---|---|---|
| Price | $8.63 | $2.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $8.50 | $7.40 |
| AVG Volume (30 Days) | 585.8K | ★ 642.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,000.00 |
| Revenue This Year | N/A | $1,010.19 |
| Revenue Next Year | $21.54 | N/A |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.66 | $0.46 |
| 52 Week High | $9.09 | $7.13 |
Technical Indicators
Market Signals| Indicator | GPRK | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 55.55 |
| Support Level | $7.74 | $2.09 |
| Resistance Level | $9.09 | $2.58 |
| Average True Range (ATR) | 0.32 | 0.15 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 66.20 | 58.97 |
Price Performance
Historical ComparisonAbout GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.